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Letters
Association
of Hemoglobin A1c Levels
With Cardiovascular
Disease and Mortality
in Chinese Patients
With Diabetes
Among diabetic patients, hemoglobin A1c (HbA1c) is
an important indicator of glycemic control and,
together with blood pressure and cholesterol, is an
indicator for risk of complications, including cardio-
vascular disease (CVD) and mortality. At present,
there is no universal consensus on the optimal HbA1c
level. Despite this, most international guidelines
include a recommended HbA1c target range or level
as a treatment goal. Several studies have identiﬁed a
J-shaped curvilinear relationship between HbA1c and
CVD incidence and all-cause mortality, but such a
relationship has not yet been conﬁrmed in a Chinese
population (1). There are substantial differences in
disease risks across racial and ethnic groups due to
genetic and environmental factors including life-style
and health behaviors, and thus, previous results from
Western studies may not be transferable to a Chinese
population (2). We sought to examine the association
among mean HbA1c, CVD events, and mortality
among Chinese primary care patients with type 2
diabetes mellitus (T2DM) in Hong Kong.
A population-based retrospective cohort study
was conducted on 117,389 Chinese adult T2DM pri-
mary care patients without any CVD history and who
had an HbA1c value recorded between August 1,
2008, and December 31, 2009. Data was extracted
from the computerized administrative database of
Hong Kong Hospital Authority. The date of the ﬁrst
recorded HbA1c was used as the baseline date for
each subject. Each subject was then tracked to
identify: the date of incidence of an outcome event,
the date of all-cause mortality, or until December 31,
2013, whichever came ﬁrst. The study outcomes
included: 1) CVD event with 1 of the following sub-
type diagnoses: coronary heart disease (CHD), stroke,
or heart failure; 2) CHD; 3) stroke; 4) heart failure;
5) all-cause mortality; and 6) CVD-related mortality.
Comorbidities were identiﬁed by the diagnosis cod-
ing system of International Classiﬁcation of Primary
Care-2 and International Classiﬁcation of Diseases,
Ninth Edition, Clinical Modiﬁcation. A “mean HbA1c”
value was determined by calculating the average of
all HbA1c measurements collected during follow-up.
Baseline covariates included: age; sex; smoking
status; drinking habit; body mass index; waist-to-hip
ratio; systolic and diastolic blood pressure; low-
density lipoprotein cholesterol; total cholesterol
to high-density lipoprotein cholesterol ratio; tri-
glycerides; urine albumin-to-creatinine ratio; self-
reported duration of diabetes; family history of
diabetes; hypertension; the stage of chronic kidney
disease; and baseline use of antihypertensive drugs,
metformin, sulfonylurea, other oral antidiabetic
drugs (acarbose, glitazone, gliptin, glucagon-like
peptide-1 agonist, and meglitinides), insulin, and
lipid-lowering agents.
Missing data (other than HbA1c) were handled
by multiple imputation method. Study subjects were
divided into 10 groups according to their mean
HbA1c measurement (<6.0%, $6.0% to <6.5%, $6.5%
to <7.0%, $7.0% to <7.5%, $7.5% to <8.0%, $8.0% to
<8.5%, $8.5% to <9.0%, $9.0% to <9.5%, $9.5%
to <10.0%, and $10.0%). The relationship between
HbA1c group and study outcomes were evaluated
using multivariable Cox Proportional Hazard regres-
sion, adjusting for all baseline covariates. The statis-
tical procedures were repeated using updated HbA1c
as a time-updated analysis.
After a median follow-up of 54.5 to 58.5 months,
amongst the 10 HbA1c groups, unadjusted incidence
rates for CVD events and all-cause mortality were 13.8
to 28.8 and 9.4 to 32.3 per 1,000 person-years,
respectively. A J-shaped curvilinear relationship was
identiﬁed between HbA1c levels and CVD incidence,
all-cause mortality, as well as other outcomes
(Figure 1). An HbA1c range of $7.0% to <7.5% had the
lowest risk of new CVD, CHD, stroke, heart failure, all-
cause mortality, and CVD-related mortality. When
compared to a HbA1c range of $7.0% to <7.5%,
HbA1c <6.5% or $8.0% was associated with a signif-
icantly higher incidence of CVD and all-cause
mortality. Similar results were obtained in the time-
updated analysis.
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FIGURE 1 Q3Adjusted Hazard Ratios for Incidence of Cardiovascular Disease, Coronary Heart Disease, Stroke, Heart Failure, All-Cause
Mortality, and Cardiovascular Disease–Related Mortality by Mean HbA1c During Follow-Up
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Blue and red lines refer to the adjusted hazard ratios and coefﬁcients of Cox proportional hazard regression, respectively. Error bars Q6indicate
95% conﬁdence intervals. HbA1c ¼ glycosylated hemoglobin.
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This study had several limitations. This was a
retrospective cohort study, which is lower in terms of
evidence hierarchy than a randomized controlled
trial. Drug exposure over time and lifestyle behavior
risk factors such as diet and exercise were not taken
into account in the analyses. This study was under-
taken in Hong Kong, and the pattern of association
between HbA1c and outcomes may differ in other
Chinese populations. The relationship may be subject
to temporal changes and modiﬁcations in unmea-
sured risk factors or interventions.
The results of this territory-wide, naturalistic,
cohort study of Chinese primary care patients with
T2DM supports the ﬁndings of previous observational
studies conducted in the United States, United
Kingdom, Denmark, and Netherlands, demonstrating
a J-shaped pattern of association between HbA1c and
CVD and all-cause mortality (1). Similar J-shaped re-
lationships were also identiﬁed for CHD, stroke, heart
failure, and CVD-related mortality. Although this
phenomenon has been postulated to be related to the
deleterious effects of severe hypoglycemia (3), this is
controversial, and it remains unclear why low levels
of HbA1c are associated with a higher risk of CVD and
all-cause mortality.
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